Navigation Links
Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Date:7/8/2008

s could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item IA. "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.


'/>"/>
SOURCE Schering-Plough Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
6. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Schering-Plough Reports Top-Line Results of the IDEAL Study
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
11. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...clinical program to evaluate TAXUS(R) Element(TM) ...Stent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCal...today announced that it has completed enrollment i...any,s third-generation,TAXUS(R) Element(TM) paclit...program has enrolled nearly 1,500 patients at 100 ...
(Date:10/7/2008)...DIEGO, Oct. 7 /- Prometheus Laborator...y announced findings from its,development of PROME...test,for irritable bowel syndrome (IBS). The findi...on of particular biomarkers in blood samples,betwe... these biomarkers,combined with a proprietary alg...
(Date:10/7/2008)...lts of FLEXX Trial Presented at the Osteoarthritis...ess, PARSIPPANY, N.J., Oct. 7 /- Fer...ts from the FLEXX Trial of Osteoarthritis of the,K...te), a highly pure,non-avian high molecular weight...is superior to intra-articular saline (IA-saline) ...
(Date:10/7/2008)... clinical study of adults, VYVANSE taken once-dail...in one week, PHILADELPHIA, Oct. 7 /PRNewswire-Fir...e global specialty biopharmaceutical company, toda...r issue of the Journal of,Clinical Psychiatry foun...ion Deficit Hyperactivity Disorder (ADHD) symptoms...
Breaking Medicine Technology:Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 1Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 2Psychemedics Corporation Announces Second Quarter Results 24442 1Psychemedics Corporation Announces Second Quarter Results 24442 2Psychemedics Corporation Announces Second Quarter Results 24442 3Psychemedics Corporation Announces Second Quarter Results 24442 4Psychemedics Corporation Announces Second Quarter Results 24442 5Arcadia Radiology Medical Group Chooses AMICAS 6758 1Arcadia Radiology Medical Group Chooses AMICAS 6758 2Arcadia Radiology Medical Group Chooses AMICAS 6758 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 1Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 2Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 4
...pyridopyrazine-urea derivative compound series sho...e valuable for cancer,treatment , , QUBEC C... (TSX: AEZ; Nasdaq:,AEZS), a global, pure play b...erapy and oncology, today presented an abstract,...e derivatives,with high selectivity for PI3K inh...
...SINESS WIRE)--Apr 17, 2007 - Alnylam,Pharmaceutica...cs,company, announced today at the American Associ...ng that it will advance a,systemically delivered R...iver cancer and potentially other solid tumors as ...erapeutic that is,designed to target vascular endo...
Other Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... nonsurgical image-guided treatment of kidney tumo...copic// technique in viable candidates. The resear...Radiology’s 32nd Annual Scientific Meeting. The ...ous cryoablation results in a slightly lower recur...
...s to help stroke survivors with the kind of comple...outside the box," according// to a University of I...participants' abilities were independent of any ch...improvements in complex mental abilities were not ...
...n are at a higher risk of perinatal mortality (dea...ies born to black or white women// , concludes a s... Health Organisation defines post-term pregnancy a...irst day of the last menstrual period. Post-term p...
...orld's largest maker of generic drugs and 19 other...ine medicines without federal approval. The Food ...s were part of an effort to halt the marketing of ...drugs. The goal is to get the unapproved drugs off...
Other Medicine News:Health News:Freezing Kidney Tumors Effective and Less Expensive Than Laparoscopy 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 3Health News:FDA Warns Migraine Medicine Makers 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: